Sanjivani Paranteral Limited Recommends Dividend for the First Time

Mumbai, Maharashtra, India – Business Wire India

For the first time in its history, Sanjivani Parenteral Limited has recommended a dividend.

The Board of Sanjivani Paranteral Ltd has recommended a final dividend of INR 0.5/- per share, i.e., 5% of equity share having face value of INR 10/- each for the financial year ended 31 March 2025 to be declared at the ensuing Annual General Meeting (AGM) of the Company. The final Dividend if declared, shall be paid within 30 days from the date of its declaration at the AGM.

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

About Sanjivani Paranteral

Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and four manufacturing plants at Navi Mumbai, Dehradun, Pimpri & Czech Republic, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

(Disclaimer: The above press release comes to you under an arrangement with Business Wire India and PTI takes no editorial responsibility for the same.). PTI PWR
PWR

(This story has not been edited by THE WEEK and is auto-generated from PTI)